134 related articles for article (PubMed ID: 27413531)
1. Evaluating the neonatal BCG vaccination programme in Ireland.
Usher C; Adams R; Schmitz S; Kieran J; O'Flanagan D; O'Donnell J; Connolly K; Corcoran B; Butler K; Barry M; Walsh C
Arch Public Health; 2016; 74():28. PubMed ID: 27413531
[TBL] [Abstract][Full Text] [Related]
2. Economic Evaluation of Selective Neonatal Bacillus Calmette-Guérin Vaccination of High-risk Infants in Ireland.
Teljeur C; Moran PS; Harrington P; Butler K; Corcoran B; O'Donnell J; Usher C; O'Flanagan D; Connolly K; Ryan M
Pediatr Infect Dis J; 2018 Aug; 37(8):759-767. PubMed ID: 29432385
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of BCG Vaccination against Tuberculosis in Indonesia: A Model-Based Study.
Machlaurin A; Dolk FCK; Setiawan D; van der Werf TS; Postma MJ
Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33256143
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of universal BCG vaccination of Japanese infants.
Rahman M; Sekimoto M; Takamatsu I; Hira K; Shimbo T; Toyoshima K; Fukui T
Int J Epidemiol; 2001 Apr; 30(2):380-5. PubMed ID: 11369746
[TBL] [Abstract][Full Text] [Related]
6. Targeted BCG vaccination against severe tuberculosis in low-prevalence settings: epidemiologic and economic assessment.
Altes HK; Dijkstra F; Lugnèr A; Cobelens F; Wallinga J
Epidemiology; 2009 Jul; 20(4):562-8. PubMed ID: 19295437
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui.
Lanckriet C; Lévy-Bruhl D; Bingono E; Siopathis RM; Guérin N
Int J Epidemiol; 1995 Oct; 24(5):1042-9. PubMed ID: 8557438
[TBL] [Abstract][Full Text] [Related]
8. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
9. Modelling the cost-effectiveness of a new infant vaccine to prevent tuberculosis disease in children in South Africa.
Channing L; Sinanovic E
Cost Eff Resour Alloc; 2014; 12():20. PubMed ID: 25242892
[TBL] [Abstract][Full Text] [Related]
10. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.
Krahn M; Detsky AS
Med Decis Making; 1993; 13(1):4-20. PubMed ID: 8433635
[TBL] [Abstract][Full Text] [Related]
11. A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guérin in Finland.
Hersh AL; Tala-Heikkilä M; Tala E; Tosteson AN; Fordham von Reyn C
Int J Tuberc Lung Dis; 2003 Jan; 7(1):22-9. PubMed ID: 12701831
[TBL] [Abstract][Full Text] [Related]
12. Non-restrictive open vial policy combined with the home visit vaccinations for improving BCG coverage in a high-incidence outreach region: A model-based cost-effectiveness analysis for Indonesia.
Machlaurin A; Luttjeboer J; Setiawan D; Sytse van der Werf T; Postma MJ
J Glob Health; 2023 May; 13():04049. PubMed ID: 37227042
[TBL] [Abstract][Full Text] [Related]
13. Disregarding the restrictive vial-opening policy for BCG vaccine in Guinea-Bissau: impact and cost-effectiveness for tuberculosis mortality and all-cause mortality in children aged 0-4 years.
Thysen SM; Fisker AB; Byberg S; Aaby P; Roy P; White R; Griffiths U; Harris RC
BMJ Glob Health; 2021 Aug; 6(8):. PubMed ID: 34344667
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England.
van Hoek AJ; Miller E
PLoS One; 2016; 11(2):e0149540. PubMed ID: 26914907
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature.
Colditz GA; Berkey CS; Mosteller F; Brewer TF; Wilson ME; Burdick E; Fineberg HV
Pediatrics; 1995 Jul; 96(1 Pt 1):29-35. PubMed ID: 7596718
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomised trial.
Pereira SM; Barreto ML; Pilger D; Cruz AA; Sant'Anna C; Hijjar MA; Ichihara MY; Santos AC; Genser B; Rodrigues LC
Lancet Infect Dis; 2012 Apr; 12(4):300-6. PubMed ID: 22071248
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of two strategies for vaccinating US veterans with hepatitis C virus infection against hepatitis A and hepatitis B viruses.
Jakiche R; Borrego ME; Raisch DW; Gupchup GV; Pai MA; Jakiche A
Am J Med Sci; 2007 Jan; 333(1):26-34. PubMed ID: 17220691
[TBL] [Abstract][Full Text] [Related]
18. Impact of BCG vaccination on incidence of tuberculosis disease in southern Ireland.
Sweeney E; Dahly D; Seddiq N; Corcoran G; Horgan M; Sadlier C
BMC Infect Dis; 2019 May; 19(1):397. PubMed ID: 31072396
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil.
Sartori AMC; de Soárez PC; Fernandes EG; Gryninger LCF; Viscondi JYK; Novaes HMD
Vaccine; 2016 Mar; 34(13):1531-1539. PubMed ID: 26899375
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland.
Tilson L; Usher C; Butler K; Fitzsimons J; O'Hare F; Cotter S; O'Flanagan D; Johnson H; Barry M
Value Health; 2008; 11(5):898-903. PubMed ID: 18489504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
